Abstract OBJECTIVE: To study serum levels of heart-type fatty acid-binding protein (h-FABP) in children with chronic heart failure (CHF), and the correlation between heart function and the level of h-FABP, with the aim of studying the significance of h-FABP in CHF. METHODS: Thirty-six children with CHF, including 16 cases of endocardial fibroelastosis (EFE) and 20 cases of dilated cardiomyopathy (DCM) were enrolled in the study. Thirty healthy children sevred as the control group. Serum levels of h-FABP were determined using ELISA, and left ventricular ejection fraction (LVEF), cardiac index (CI) and fractional shortening of the left ventricle (LVSF) were measured by two-dimensional echocardiography in the CHF group. RESULTS: Mean levels of h-FABP in the CHF group were significantly higher than in the control group (21.7±4.3 ng/mL vs 6.2±1.7 ng/mL; P<0.01). The worse the heart function, the higher the h-FABP levels (P<0.01). Mean levels of h-FABP in both the EFE and DCM groups were significantly higher than in the control group (P<0.01). Serum h-FABP concentrations were negatively correlated with LVEF, CI and LVSF (r=-0.65, -0.64 and -0.71 respectively; P<0.01) in the CHF group. CONCLUSIONS: Serum h-FABP levels increase in children with CHF and are closely related to the severity of the condition. Serum h-FABP levels can be used as a biomarker for the diagnosis of heart failure and the evaluation of its severity.
SUN Yu-Ping,WANG Wen-Di,MA Shao-Chun et al. Changes of heart--type fatty acid-binding protein in children with chronic heart failure and its significance[J]. CJCP, 2013, 15(2): 99-101.
SUN Yu-Ping,WANG Wen-Di,MA Shao-Chun et al. Changes of heart--type fatty acid-binding protein in children with chronic heart failure and its significance[J]. CJCP, 2013, 15(2): 99-101.
［1］Valle HA, Riesgo LC, Bel MS, Gonzalo FE, Sanchez MS, Oliva LI. Clinical assessment of heart-type fatty acid binding protein in early diagnosis of acute coronary syndrome［J］. Eur J Emerg Med, 2008, 15 (3): 140-144.
［2］Garcia-Valdecasas S, Ruiz-Alvarez MJ, Garcia De Tena J, De Pablo R, Huerta I, Barrionuevo M, et al. Diagnostic and prognostic value of heart-type fatty acid-binding protein in the early hours of acute myocardial infarction［J］. Acta Cardiol, 2011, 66(3): 315-321.
［6］Bruins Slot MH, Reitsma JB, Rutten FH, Hoes AW, van der Heijden GJ. Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction: a systematic review and meta-analysis［J］. Heart, 2010, 96(24): 1957-1963.
［7］Colli A, Josa M, Pomar JL, Mestres CA, Gherli T. Heart fatty acid binding protein in the diagnosis of myocardial infarction: Where do we stand today?［J］. Cardiology, 2007, 108(1): 4-10.
［8］Figiel L, Kasprzak JD, Peruga J, Lipiec P, Drozdz J, Krzeminska-Pakula M, et al. Heart-type fatty acid binding protein-a reliable marker of myocardial necrosis in a heterogeneous group of patients with acute coronary syndrome without persistent ST elevation［J］. Kardiol Pol, 2008, 66(3): 253-259.
［9］Niizeki T, Takeishi Y, Arimoto T, Takabatake N, Nozaki N, Hirono O, et al. Combination of heart-type fatty acid binding protein and brain natriuretic peptide can reliably risk stratify patients hospitalized for chronic heart failure［J］. Circ J, 2005, 69(8): 922-927.
［10］Komamura K, Sasaki T, Hanatani A, Kim J, Hashimura K, Ishida Y, et al. Heart-type fatty acid binding protein is a novel prognostic marker in patients with non-ischemic dilated cacdiomyopathy［J］. Heart, 2006, 92(5): 615-618.
［11］O′Donoghue M, de Lemos JA, Morrow DA, Murphy SA, Buros JL, Cannon CP, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes［J］. Circulation, 2006, 114(6): 550-557.
